# Missing Data Analysis & Improvement Plan

## üîç **CURRENT DATA STATUS**

### **‚úÖ COMPLETED**
- **Azacitidine Clinical Efficacy**: 75/169 papers with efficacy data
- **Adverse Events Data**: Available but limited structured data
- **Dashboard**: Updated with accurate statistics

### **‚ùå MISSING/INSUFFICIENT DATA**

#### **1. PFS (Progression-Free Survival) Data**
- **Current**: Only 7 papers with PFS data out of 75 efficacy papers
- **Issue**: Original extraction prompt wasn't comprehensive enough
- **Solution**: Enhanced extraction script with better prompts

#### **2. Therapy Duration/Cycles Data**
- **Current**: No structured therapy duration data
- **Issue**: Not specifically targeted in original extraction
- **Solution**: Enhanced extraction script includes therapy duration fields

#### **3. Adverse Events by Individual Drug**
- **Current**: Limited structured AE data (18 azacitidine, 1 decitabine papers)
- **Issue**: AE data exists but not in standardized format
- **Solution**: Enhanced extraction integrates AE data

#### **4. Decitabine Clinical Efficacy**
- **Current**: Extraction in progress (125 papers)
- **Issue**: Not completed yet
- **Solution**: Continue extraction

#### **5. Hydroxyurea Clinical Efficacy**
- **Current**: Not started (9 papers)
- **Issue**: Not extracted yet
- **Solution**: Create extraction script

## üõ†Ô∏è **IMPROVEMENT ACTIONS**

### **1. Enhanced Clinical Efficacy Extraction**
**Script**: `extract_clinical_efficacy_enhanced.py`
**Improvements**:
- Better prompts for PFS data extraction
- Specific therapy duration/cycles extraction
- Integrated adverse events extraction
- More comprehensive field coverage

**Expected Results**:
- More PFS data (target: 20+ papers)
- Therapy duration data (target: 15+ papers)
- Better adverse events integration

### **2. Adverse Events Analysis**
**Current Status**: 
- 18 azacitidine papers with AE data
- 1 decitabine paper with AE data
- Limited structured metrics

**Available Data Types**:
- Any grade AE rates
- Grade 3-4 AE rates
- Serious AE rates
- Treatment-related AE rates
- Discontinuation rates
- Dose reduction rates

### **3. Missing Metrics Breakdown**

#### **PFS Data Missing**
- **Why**: Original prompt didn't emphasize PFS extraction
- **Solution**: Enhanced prompt specifically targets:
  - "median PFS", "PFS", "progression-free"
  - "time to progression"
  - Multiple timepoints

#### **Therapy Duration Missing**
- **Why**: Not specifically targeted
- **Solution**: Enhanced prompt targets:
  - "cycles", "duration", "treatment period"
  - "median cycles", "number of cycles"

#### **Adverse Events Limited**
- **Why**: Data exists but not standardized
- **Solution**: Enhanced extraction integrates AE data

## üìä **DATA QUALITY ASSESSMENT**

### **Azacitidine (169 papers)**
- ‚úÖ **Complete Response**: 30 studies (good coverage)
- ‚úÖ **Overall Response Rate**: 53 studies (excellent coverage)
- ‚úÖ **Overall Survival**: 38 studies (good coverage)
- ‚ùå **PFS**: 7 studies (needs improvement)
- ‚ùå **Therapy Duration**: 0 studies (needs extraction)
- ‚ö†Ô∏è **Adverse Events**: 18 studies (limited structured data)

### **Decitabine (125 papers)**
- ‚ùå **All Clinical Efficacy**: Extraction in progress
- ‚ö†Ô∏è **Adverse Events**: 1 study (very limited)

### **Hydroxyurea (9 papers)**
- ‚ùå **All Clinical Efficacy**: Not extracted
- ‚ùå **Adverse Events**: Not extracted

## üéØ **IMMEDIATE NEXT STEPS**

### **Priority 1: Enhanced Extraction**
1. **Run enhanced extraction** for azacitidine (in progress)
2. **Monitor results** for PFS and therapy duration improvements
3. **Update dashboard** with enhanced data

### **Priority 2: Complete Decitabine**
1. **Continue decitabine extraction** (in progress)
2. **Apply enhanced prompts** to decitabine extraction
3. **Generate decitabine statistics**

### **Priority 3: Hydroxyurea**
1. **Create hydroxyurea extraction script**
2. **Run extraction** for 9 hydroxyurea papers
3. **Generate hydroxyurea statistics**

### **Priority 4: Combined Analysis**
1. **Calculate combined azacitidine + decitabine statistics**
2. **Generate comparative analysis**
3. **Update dashboard** with all three drugs

## üìà **EXPECTED IMPROVEMENTS**

### **After Enhanced Extraction**
- **PFS Data**: 7 ‚Üí 20+ papers (3x improvement)
- **Therapy Duration**: 0 ‚Üí 15+ papers (new data)
- **Adverse Events**: Better integration with clinical data

### **After Decitabine Completion**
- **Total Efficacy Papers**: 75 ‚Üí 150+ papers
- **Combined Analysis**: Full azacitidine + decitabine comparison
- **Statistical Power**: Much stronger comparative analysis

### **After Hydroxyurea**
- **Complete Dataset**: All three drugs analyzed
- **Comprehensive Comparison**: Full three-way analysis
- **Dashboard Completion**: All metrics populated

## üîß **TECHNICAL IMPROVEMENTS**

### **Enhanced Prompt Features**
1. **Specific PFS targeting**: "Look for: 'median PFS', 'PFS', 'progression-free'"
2. **Therapy duration targeting**: "Look for: 'cycles', 'duration', 'treatment period'"
3. **Comprehensive AE integration**: All AE metrics in one extraction
4. **Better confidence scoring**: More accurate extraction confidence

### **Data Structure Improvements**
1. **Enhanced fields**: More comprehensive data capture
2. **Better validation**: Improved data quality checks
3. **Integration**: Clinical efficacy + adverse events in one record

---

**Last Updated**: 2025-08-16 14:45:00
**Status**: Enhanced extraction in progress, comprehensive analysis planned
